Chemical Exfoliation Formulation: AHA, BHA or PHA for Brands
Quick answer
This guide covers acid-based chemical exfoliation in skincare; enzyme exfoliants are outside its scope. For a brand, four decisions follow from the intended use:
- Market and claim route. Name destination markets and write the intended claims before choosing an acid. Acne treatment language, for example, changes the US regulatory route.
- Acid family and role. Compare AHA, BHA and PHA against the appearance or sensory target you want to test.
- Single acid or blend. A blend adds variables, market checks and evidence work. It needs a reason you can name.
- Format and contact time. A leave-on toner, a pad and a rinse-off cleanser are different products, even with the same acids.
Acid families behave differently, but no family label describes your finished product. FDA states that the extent of AHA exfoliation "depends on the type and concentration of the AHA, its pH, and other ingredients in the product." Apply the same caution to every comparison in this guide. The finished formula decides the result, and finished-product evidence decides the claim.
This guide is for brand owners, product developers and buyers briefing a manufacturer. It is not consumer advice. Our single-acid guides cover salicylic, glycolic and lactic acid in depth. This one covers how to choose between acid systems and how to brief a finished exfoliating product.
AHA vs BHA vs PHA: a comparison for product briefs
Swipe or scroll horizontally to compare all columns.
| Acid system | Where brands usually position it | What the formulator has to manage | Regulatory and claim watch-points | What only finished-product work can show |
|---|---|---|---|---|
| AHA: glycolic acid | Texture and "smoother-looking skin" stories; the most familiar exfoliating acid | Content and final pH as separate numbers; low-pH stability; pack contact materials | US: assess FDA Sunburn Alert guidance where applicable; avoid drug-treatment claims | Exfoliation or texture claims; tolerance at the stated frequency |
| AHA: lactic acid | Texture plus a skin-feel or hydration story | Whether it exfoliates or only adjusts pH; balance with sodium lactate | Same US AHA labeling question; role decides which claims are possible | Any "gentler" or "hydrating" claim |
| BHA: salicylic acid | Oily-looking skin, visible pores, congestion-led appearance stories | Keeping the acid dissolved in the base at the target pH; after-feel | US: an acne claim moves the product to the OTC drug route. EU: own conditions of use (see below) | Pore and oil-appearance claims; tolerance |
| PHA: gluconolactone | A different sensory positioning to test; possible supporting role in a blend | Its contribution next to other acids; stability in the base | Check ingredient and claim conditions in each market | Any "gentle", "daily" or "sensitive skin" wording |
| Multi-acid blend | "Complete" exfoliation stories across texture and pores | Combined pH, cumulative exposure, interaction with other actives | Every acid checked separately in every market | Claims on the combination, not on each acid's reputation |
Salicylic acid vs glycolic acid. Choose by position, not strength. Salicylic acid fits an oil- and pore-appearance product. In the United States, adding acne language moves it into drug rules. Glycolic acid fits a texture product and brings the US AHA sun-sensitivity labeling question with it. Many brands that want both stories put the two acids in one blend. That works only if the brief can say what each acid is there to do.
Glycolic acid vs lactic acid. Both are AHAs, but an ingredient name cannot establish relative tolerance in a finished formula. Our lactic acid guide explains why "lactic is gentler" is a hypothesis to test on matched samples, not a specification.
Single acid or a blend
A blend can support several stories: texture from an AHA, pore appearance from salicylic acid and a different sensory direction from a PHA. It also adds development work:
- More market checks. Each acid has its own conditions and claim limits in each destination market.
- More variables. pH, solubility, stability and pack compatibility are judged for the combination, not for each acid alone.
- Cumulative exposure. Each acid being within its own guideline does not make the blend suitable at your intended frequency.
- Clearer decision record. Compare the blend with a single-acid version in the same format. If the extra acid adds no testable difference to the target product, the added complexity needs a better reason.
A practical rule: start with a single acid unless your positioning needs two effects that you can name, test and keep separate in the claim set. If the second acid exists only to make the label longer, leave it out.
Leave-on or rinse-off
Contact time changes the brief more than the acid name does.
- Leave-on toner, serum or lotion. The acid stays on the skin until the next cleanse. Use frequency, sun-protection directions and tolerance evidence matter most. Our glycolic acid guide compares leave-on formats in detail.
- Pre-soaked pads. Leave-on exposure plus pack questions: liquid volume per pad, evaporation once the jar is opened, saturation at the bottom of the jar.
- Rinse-off cleanser or wash-off mask. Contact time is shorter. Ask whether the acid is there to exfoliate or only to set pH. An exfoliation claim needs evidence on the rinse-off product itself.
Rinse-off use alone is not a reason to skip the US AHA labeling review. FDA's AHA labeling guidance expressly considers short-contact, thoroughly rinsed "discontinuous use" products, subject to its other scope conditions. That does not mean every rinse-off product needs the same warning; check the finished product and intended use.
Claim and market boundaries
Check each claim line against the exact wording, the finished formula and each destination market.
United States
- Intended use decides the category. FDA classifies a product as a cosmetic or a drug by its intended use. Intended use can be shown by claims on labels, in advertising and online, and by consumer perception.
- Acne treatment follows a drug route. FDA identifies acne treatment as a drug intended use, including when that intent appears in online claims. A brand planning an acne product needs a separate review of the current OTC acne order and drug labeling; do not borrow drug active ranges as cosmetic formulation targets. Keep treatment wording out of a cosmetic exfoliant brief across all channels.
- AHA sun sensitivity. FDA's AHA labeling guidance recommends a Sunburn Alert for topically applied AHA cosmetics within the guidance's scope. FDA states that guidance documents are recommendations, not legally enforceable requirements, and that this guidance does not apply where an AHA is only an incidental ingredient. The glycolic acid guide covers how to plan this.
- Peel and treatment language. FDA notes that more serious AHA adverse reactions appear most often with products that exfoliate most, such as "skin peelers". It identifies acne treatment and skin lightening as drug intended uses. Have a regulatory specialist review peeling claims and exclude treatment promises, including scar removal, from a cosmetic claim set.
- Safety substantiation. Under MoCRA, the US responsible person named on the label must ensure and maintain records supporting adequate safety substantiation for the cosmetic. Agree which ingredient and finished-product data the manufacturer will supply; that agreement does not transfer the responsible person's duty.
European Union
The current consolidated Regulation (EC) No 1223/2009 lists salicylic acid in Annex III, entry 98, with conditions that differ by product type and use. Check the finished product against that entry before fixing an EU formula or claim. Under Article 10, the EU Responsible Person must ensure a finished-product safety assessment and cosmetic product safety report before placing it on the market. A supplier sheet or competitor label cannot replace those checks. Our salicylic acid guide explains why the entry is not a simple leave-on versus rinse-off split.
Other markets
ASEAN, UK, China and Gulf markets set their own ingredient conditions and claim rules. A formula or claim accepted in one market proves nothing about another. Get a per-market answer before sampling.
The sample brief: what to send
A brief for a chemical exfoliation product should let a formulator propose a route and let you judge samples against a written target.
- Destination markets, in launch order.
- Claim lists: intended claims word for word, possible claims if evidence supports them, and excluded claims such as acne treatment or peel wording.
- Product format and contact time: leave-on, pad or rinse-off; how often and for how long it is used.
- Acid direction: AHA, BHA, PHA or blend, with the reason for each acid. Leave levels and pH open unless you have a reason to fix them.
- Intended user and exclusions: the skin types you design for, and groups you will not target.
- Sensory target: texture, tingle tolerance on application, after-feel, residue, fragrance-free or scented.
- Packaging: pack type, materials, closure and applicator, or your own components.
- Other actives in the formula or the wider range, so cumulative exposure can be reviewed.
- What you want quoted: samples only, or samples plus stability, compatibility, preservative efficacy, tolerance and claim studies.
- Quantity range per SKU.
Ask the manufacturer to confirm in writing, for each sample: each acid by INCI name and function, content on a stated basis, target and measured final pH, a unique formula code, and which market rules were checked and by whom.
For an EU launch, name the EU Responsible Person in the project plan and agree who will supply the data needed for the required safety assessment and safety report. For a US launch, agree what data the label's responsible person needs to keep for safety substantiation.
Briefing an exfoliant? Send your markets, format, acid direction and draft claims. Ask for sample and testing scope in the quotation.
Send a product briefComparing samples and testing scope
When deciding whether a blend adds value, request a single-acid comparator in the same format, pack and use schedule. Record a formula code, each acid's role and content basis, and measured final pH for every version. Compare sensory notes and visible changes without treating a team trial as tolerance or efficacy evidence.
For each version, ask what stability, preservative and packaging-compatibility work is proposed in the final pack. A blend may change solubility, pH drift or pad saturation; a good day-one sample cannot establish shelf life. Put the test conditions, duration, provider and quote status in writing. Finished-product tolerance and benefit claims need separate evidence planned for the exact wording. Our cosmetic efficacy testing guide explains how to match a claim to a study endpoint.
How we approach exfoliating product projects
Our ODM development service can start from your markets, format, acid direction, packaging and draft claim set. The quotation should state the proposed formula-development work, claim-support scope, testing, schedule and supply terms for your project. Formal stability, packaging compatibility, preservative-efficacy, tolerance and claim studies are scoped and quoted per project. For an EU launch, agree what manufacturing data will be supplied to the Responsible Person for the required safety assessment and report; for a US launch, agree what data the label's responsible person needs for safety substantiation.
MOQ and lead time are confirmed in the quotation for the selected formula and packaging.
Summary
- Set destination markets and exact claims first; then choose acid role, single acid or blend, and format with contact time.
- Treat "AHA", "BHA" and "PHA" as starting points. Finished-formula content, pH and base decide the product.
- Every acid in a blend needs its own market check, and the claim needs evidence on the blend.
- In the US, acne-treatment wording requires a drug-route review, and an AHA cosmetic needs a scope-specific sun-sensitivity labeling decision.
- Code every sample, record measured pH, and keep sensory notes separate from stability, tolerance and claim evidence.
Frequently asked questions
Is AHA or BHA better for a first exfoliating product?
Neither is better in general. Choose by position: AHA for texture-led products, salicylic acid for oil- and pore-appearance products. Check the claim route in each market before deciding, especially if your audience expects acne language.
When should a brand consider a PHA in an exfoliant brief?
PHAs such as gluconolactone are polyhydroxy acids. A brand may explore a different sensory profile or a supporting role in a blend. Relative mildness, "gentle" and "for sensitive skin" all need evidence on the finished formula, intended users and use schedule.
Should our brief specify acid percentages?
Usually not. Ask the manufacturer to propose content and final pH together for your format, frequency and markets, with the basis written out. A percentage without a pH and a stated basis does not define the product.
Does a triple-acid toner need different checks from a single-acid toner?
Yes. Each acid is checked against each market's rules, the combination is judged for cumulative exposure and stability, and effect claims need evidence on the blend itself.
Sources (accessed 2026-11-16)
- U.S. FDA. Alpha Hydroxy Acids.
- U.S. FDA. Guidance for Industry: Labeling for Cosmetics Containing Alpha Hydroxy Acids. January 2005.
- U.S. FDA. Is It a Cosmetic, a Drug, or Both? (Or Is It Soap?).
- U.S. FDA. Modernization of Cosmetics Regulation Act of 2022 (MoCRA).
- EUR-Lex. Regulation (EC) No 1223/2009, consolidated text dated 18 May 2026; Article 10 and Annex III entry 98.
Ready to Start Your Project?
Tell us your product requirements. Within 24 hours, our technical team will reply with a quotation or the questions needed to prepare one.